DHEA vs placebo or control: Side effects ‐ androgenic side effects number of events
DHEA may leads to higher side effects ‐ androgenic side effects number of events compared with control (placebo or no treatment) (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
DHEA vs control (placebo or no treatment) Side effects ‐ androgenic side effects number of events · women in the peri‐ or postmenopausal phase DHEA may leads to higher side effects ‐ androgenic side effects number of events compared with control (placebo or no treatment) (low certainty). Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane Headline outcomes only | OR 6.57 [1.37, 31.59] | 1 study · 92 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.